Skip to Content

Paromomycin Pregnancy and Breastfeeding Warnings

Paromomycin is also known as: Humatin, Paromycin

Medically reviewed on June 11, 2018

Paromomycin Pregnancy Warnings

Paromomycin has not been formally assigned to a pregnancy category by the FDA. Paromomycin is poorly absorbed from the gastrointestinal tract; therefore, little drug would be available to reach the fetus. There are no data linking the use of paromomycin to congenital malformations or fetal toxicity, although there are no controlled data in human pregnancy. In pregnant patients with symptomatic protozoan or tapeworm infections, paromomycin may be a therapeutic option. Paromomycin should only be given during pregnancy when there are no alternatives and benefit outweighs the risk.

In one report, two women were treated with paromomycin for 10 days for symptomatic Giardia infections during the 10th and 20th week of pregnancy. No congenital malformations or fetal toxicity were reported.

See references

Paromomycin Breastfeeding Warnings

Paromomycin is poorly absorbed from the gastrointestinal tract; therefore, any excretion into breast milk is expected to be minimal.

See references

References for pregnancy information

  1. "Product Information. Humatin (paromomycin)." Parke-Davis, Morris Plains, NJ.
  2. Kreutner AK, Del Bene VE, Amstey MS "Giardiasis in pregnancy." Am J Obstet Gynecol 140 (1981): 895-901

References for breastfeeding information

  1. "Product Information. Humatin (paromomycin)." Parke-Davis, Morris Plains, NJ.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide